文献速递乳腺癌

BBOX1被鉴定为三阴性乳腺癌治疗靶点

Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer.
PubMed 文献 · Cancer Discov · 2020-07-20

该研究通过针对2-OG依赖酶的功能性siRNA筛选,发现γ-丁基甜菜碱羟化酶1(BBOX1)是三阴性乳腺癌(TNBC)肿瘤发生的关键基因。BBOX1缺失抑制TNBC细胞生长而不影响正常乳腺细胞,机制上BBOX1以酶依赖方式结合IP3R3并阻止其泛素化和蛋白酶体降解,从而维持钙依赖性能量生成过程。遗传缺失或药理抑制BBOX1在体外和体内均抑制TNBC肿瘤生长,提示BBOX1-IP3R3-钙信号轴是潜在治疗靶点。

要点

  • BBOX1是TNBC肿瘤发生必需基因,缺失抑制癌细胞生长而不影响正常乳腺细胞。
  • BBOX1通过酶依赖方式结合IP3R3并阻止其泛素化降解,维持钙依赖性线粒体呼吸和mTORC1糖酵解。
  • 遗传缺失或药理抑制BBOX1在体外和体内均抑制TNBC肿瘤生长。

核心结论

  • BBOX1是TNBC的潜在治疗靶点,靶向BBOX1-IP3R3-钙信号轴可抑制TNBC肿瘤生长。

研究设计与样本

  • 研究采用针对2-OG依赖酶的功能性siRNA筛选,鉴定TNBC肿瘤发生必需基因。

主要发现

  • BBOX1缺失抑制TNBC细胞生长而不影响正常乳腺细胞。
  • BBOX1以酶依赖方式结合IP3R3并阻止其泛素化和蛋白酶体降解。
  • BBOX1缺失抑制IP3R3介导的内质网钙释放,损害线粒体呼吸和mTORC1介导的糖酵解,导致TNBC细胞凋亡和细胞周期进展受损。
  • 遗传缺失或药理抑制BBOX1在体外和体内均抑制TNBC肿瘤生长。

临床怎么用

  • BBOX1抑制剂可能为TNBC提供新的靶向治疗策略,但需进一步开发有效抑制剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Triple-negative breast cancer (TNBC) is an aggressive and highly lethal disease. Because of its heterogeneity and lack of hormone receptors or HER2 expression, targeted therapy is limited. Here, by performing a functional siRNA screening for 2-OG-dependent enzymes, we identified gamma-butyrobetaine hydroxylase 1 (BBOX1) as an essential gene for TNBC tumorigenesis. BBOX1 depletion inhibits TNBC cell growth while not affecting normal breast cells. Mechanistically, BBOX1 binds with the calcium channel inositol-1,4,5-trisphosphate receptor type 3 (IP3R3) in an enzymatic-dependent manner and prevents its ubiquitination and proteasomal degradation. BBOX1 depletion suppresses IP3R3-mediated endoplasmic reticulum calcium release, therefore impairing calcium-dependent energy-generating processes including mitochondrial respiration and mTORC1-mediated glycolysis, which leads to apoptosis and impaired cell-cycle progression in TNBC cells. Therapeutically, genetic depletion or pharmacologic inhibition of BBOX1 inhibits TNBC tumor growth in vitro and in vivo. Our study highlights the importance of targeting the previously uncharacterized BBOX1-IP3R3-calcium oncogenic signaling axis in TNBC. SIGNIFICANCE: We provide evidence from unbiased screens that BBOX1 is a potential therapeutic target in TNBC and that genetic knockdown or pharmacologic inhibition of BBOX1 leads to decreased TNBC cell fitness. This study lays the foundation for developing effective BBOX1 inhibitors for treatment of this lethal disease.This article is highlighted in the In This Issue feature, p. 1611.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Liao C, Zhang Y, Fan C, et al. Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer. Cancer Discov. 2020. PMID: 32690540. doi:10.1158/2159-8290.CD-20-0288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。